单克隆抗体对高血压、冠心病及糖尿病患者血小板聚集的体外抑制作用

Inhibition Effect of Monoclonal Antibody on the Platelet Aggregation of Patients with Ischemic Heart Disease,Hypertension and Diabetes in Vitro

用抗血小板膜糖蛋白Ⅱb-Ⅲa复合物（GPⅡb-Ⅲa）CDw41单克隆抗体体外抑制ADP诱导血小板聚集方法，间接判断冠心病、高血压和糖尿病患者血小板表面Ⅱb-Ⅲa受体的密度。共测定51例，其中冠心病10例，高血压10例，糖尿病15例，正常对照16例。结果表明，三组患者富血小板血浆加入抗CDw41单抗后，ADP诱导的血小板聚集与正常对照组比较明显升高（P＜0．001），血小板聚集百分抑制率与正常对照组比较明显降低（P＜0．001）。本实验方法简单，结果可靠，值得临床应用。

In this paper,we utilized monoclonal antibody (MAb),antiplatelet membrane glycoprotein (GP) Ⅱ b- Ⅲ a complex (CDw41) to inibite adenosine diphosphate (ADP) -induced platelet aggregation in vitro,to assess the receptor density of GP Ⅱ b- Ⅲ a in patients with ischemic heart disease,hyertension and diabetes mellitus. Of the 51 samples were investigated, 10 were patients with coronary heart disease, 10 cases hypertension, 15 diabetes and 16 normal donors as control. Our data indicated that anti-CDw41 MAb was added to platelet-rich plasma (PRP) of these patients,the platelet aggregation in response to ADP was higher and the mean inhibited rate was lower than that in normal (P< 0. 001, P< 0. 001, respectively).This method was simple,the results were reliable,it may be valuable to use in clinics.